Consultez les derniers articles autour de la maladie de Willebrand
Dernière mise à jour : Mardi 16 avril 2024Von Willebrand disease (VWD) is the commonest inherited bleeding disorder with approximately one in 1000 of the population experiencing bleeding symptoms due to either reduced levels or dysfunctional von...
Lire la suite
This guideline updates the previous guidelines published on behalf of the British Society for Haematology (BSH) and the United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO), focussing on the...
Lire la suite
Evaluating a patient suspected of having a mild to moderate bleeding disorder (MBD) is one of the more challenging tasks in hematology. Many features of the bleeding history are subjective, distinguishing...
Lire la suite
Antifibrinolytic agents are frequently used to treat patients with bleeding disorders. These agents are lysine analogues that exert their haemostatic effects by binding to plasminogen and inhibiting its interaction with fibrin, thus reducing fibrinolysis. Antifibrinolytics have been shown to be effective in numerous clinical settings, including surgery, oral bleeding, epistaxis, and menorrhagia; their efficacy is maintained in patients with and without...
Lire la suite
2 Diagnosis and treatment of von Willebrand disease in 2024 and beyond
Haemophilia 2024; 30(S3): 103-113 Real-world evidence for coverage determination of treatments for rare diseases
Orphanet Journal of Rare Diseases 2024; 19(1): 47